WuXi adds US-based clinical research firm to CRO business

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/NicoElNino)
(Image: Getty/NicoElNino)

Related tags: Wuxi apptec, Wuxi, clinical services, Clinical development, biometrics, preclinical development

WuXi AppTec acquires Pharmapace to bolster its biometrics and clinical development service offerings worldwide.

Following the transaction, financial terms of which were not discosed, Pharmapace will become a wholly-owned subsidiary of WuXi AppTec’s clinical contract research organization (CRO) arm, WuXi Clinical.

Pharmapace, a US-based clinical research services company, provides biometrics services across all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing.

Based in San Diego, CA, the addition of Pharmapace enables WuXi Clinical to provide global customers with around-the-clock service.

“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services globally,”​ said Edward Hu, co-CEO of WuXi Apptec in a statement.

In addition to providing full clinical development services, WuXi clinical is a functional service provider (FSP).

Larry Shen, president and CEO of Pharmapace, added, “This combination now allows us to leverage WuXi Apptec’s vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission.”

WuXi AppTec has not responded to a request for comment.

Chinese regulatory reform

After the passing of regulatory reforms​, China can now accept clinical trial data from outside countries, creating opportunities for regional and global collaboration.

Following this change, among other recent reforms, WuXi AppTec acquired US-based ResearchPoint Global​ to expand its clinical research capabilities.

With the acquisition of Pharmapace, WuXi Clinical will have more than 850 employees in China and the US.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars